AN ACCOUNTABILITY COMETH: AMEND 42 USC SECTION 1983 AND 18 USC SECTIONS 241, 242, THEREBY INITIATING A PATH TO REIMAGINING PEACE OFFICERS ACTING UNDER THE COLOR OF STATE LAWDURANT III, JAMES M.DePaul Journal for Social Justice
242, as amended, without previously obtaining the permission of the owner or the master of such vessel; orWhoever brings, carries, or possesses any such weapon or explosive on board of any vessel in the possession and under the control of the United States or which has been seized and ...
TOS1X-2* Ni-18Cr-9Mo-12.5Co-1.25Al-1.35Ti-TaNb Note: * developed in Japan. HR6W was originally developed for SH tube applications. Due to its excellent creep and creep-fatigue properties and fabricability, HR6W has also been found suitable for application to thick section boiler components...
1600公告Current report, items 1.01, 2.03, and 9.01芝加哥商业交易所04-28 18:36 1740公告Additional definitive proxy soliciting materials a芝加哥商业交易所04-27 03:43 1400公告Current report, items 2.02 and 9.01芝加哥商业交易所04-26 19:27
6650公告Report of proposed sale of securities嘉年华邮轮(US)资10-29 18:25 6743卖飞了,你飞吧[滴汗]乌龟也能上高速10-15 21:35 5530不容易呀!终于跟上指数的节奏了!股友3ZeC3F10-10 03:56 511120.4美元平仓掉四分之一仓位嘉年华邮轮,套利20%轩辕资本10-09 23:55 ...
6980公告[Amend] Annual report [Section 13 and 15(d), not SCerulean Pharma06-14 07:02 5710公告Current report, item 5.02Cerulean Pharma06-10 06:53 5410公告Current report, item 3.01Cerulean Pharma06-05 22:08 5850公告Current report, items 1.02 and 9.01Cerulean Pharma06-01 20:18 ...
ClearPoint Neuro Inc吧(clpt.us) 美股市场人气排名第3259名详情 --- - 今开:- 昨收:- 最高:- 最低:- 成交量:- 振幅:- F10档案:核心必读公司概况财务分析股本股东分红派息主营构成高管研究资产负债表综合损益表现金流量表董事及股东权益更多 排序:...
3050公告Current report, items 1.01 and 9.01中点能源资讯10-31 18:16 3060公告Prospectus [Rule 424(b)(2)]中点能源资讯10-31 06:24 2990公告Filing under Securities Act Rules 163/433 of free中点能源资讯10-30 06:05 2950公告Prospectus [Rule 424(b)(5)]中点能源资讯10-29 20:51 ...
10-18 06:01 701 0 公告Post-Effective amendments for registration statement Cerulean Pharma 资讯 10-14 04:19 242 0 公告Notice of Effectiveness Cerulean Pharma 资讯 10-14 00:00 740 0 公告Statement of changes in beneficial ownership of securities ...
18. The method of claim 6, wherein contacting or amplifying comprises use of methylation-specific primers. 19. The method of claim 6, further comprising contacting the treated genomic DNA, or the at least one treated fragment thereof, with an amplification enzyme and at least one primer compri...